In vivo evaluation of [123I]mZIENT as a SPECT radioligand for the serotonin transporter

[123I] mZIENT demonstrates good test-retest reproducibility; and initial displacement studies suggest that this compound is highly selective for SERT. Overall, this radioligand has favorable characteristics for use in drug development studies and/or longitudinal studies interrogating SERT.